Juan C. Jaen, president of Arcus Biosciences, sold 68,569 shares for $2.0 million through a trust under a Rule 10b5-1 trading plan, while maintaining ~1.2 million shares. The sale appears motivated by tax and liquidity management following a 200% stock surge. Arcus has refocused on casdatifan, its HIF-2α kidney cancer drug, after discontinuing a lung cancer program, with pivotal Phase 3 readouts expected by year-end.

The article discusses the global surge in cancer cases, particularly among people under 50, and the efforts of biotech companies to develop new therapies to combat this trend. It highlights recent progress and upcoming studies from several companies in the oncology space.

The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.

Arcus Biosciences (RCUS) underwent analysis by 4 analysts in the last quarter, with a downward trend in their 12-month price targets. The article provides a detailed breakdown of the analysts' recent evaluations, ratings, and price targets for the company.

Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.

Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.

This article discusses upcoming market events and earnings reports, including the CoinDesk Consensus event and the release of the personal income and...

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 94.85% and 454.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In the latest quarter, 5 analysts provided ratings for Arcus Biosciences (NYSE:RCUS), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Arcus Biosciences, presenting an average target of $37.6, a high estimate of $50.00, and a low estimate of $30.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.56%. Diving into Analyst Ratings: An In-Depth Exploration A clear picture of Arcus Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robyn Karnauskas Truist Securities Maintains Buy $50.00 - Robert Driscoll Wedbush Maintains Outperform $30.00 - Robert Driscoll Wedbush Lowers Outperform $30.00 $36.00 Mara Goldstein Mizuho Lowers Buy $42.00 $51.00 Robert Driscoll Wedbush Maintains Outperform $36.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcus Biosciences. This information provides a snapshot ...Full story available on Benzinga.com

The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.